The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", 3 "hold" and no "sell" or "strong sell".
The average consensus recommendation for the healthcare facilities & services peer group is "buy".
Wall Street's median 12-month price target for Aveanna Healthcare Holdings Inc is $11.00, about 21.5% above its August 12 closing price of $9.05.
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 10 three months ago.
Guidance raised on segment growth
Aveanna Healthcare raises full-year 2026 revenue guidance to greater than $2.68 bln.
Company lifts full-year 2026 adjusted EBITDA guidance to greater than $365 mln.
Aveanna cites strong segment performance and strategic execution for improved outlook.
SEGMENT GROWTH - Revenue increase driven by growth across PDS, HHH, and MS segments.
ORGANIC GROWTH - Co cited strong organic growth across all three business segments.
ACQUISITION IMPACT - Acquisition of Family First contributed to performance, per CFO.
Quarterly results beat expectations
US home care provider's Q2 revenue rose 13.7%, beating analyst expectations.
Adjusted EBITDA for Q2 increased 8.0% year-over-year.
AVAH•
